Ferroptosis in colorectal cancer: a future target?

Hong Yan, Ronan Talty, Oladimeji Aladelokun, Marcus Bosenberg, Caroline H Johnson

Journal: British journal of cancer 2023;128(8):1439-1451

PMID: 36703079

Abstract

Colorectal cancer (CRC) is the third leading cause of cancer deaths worldwide and is characterised by frequently mutated genes, such as APC, TP53, KRAS and BRAF. The current treatment options of chemotherapy, radiation therapy and surgery are met with challenges such as cancer recurrence, drug resistance, and overt toxicity. CRC therapies exert their efficacy against cancer cells by activating biological pathways that contribute to various forms of regulated cell death (RCD). In 2012, ferroptosis was discovered as an iron-dependent and lipid peroxide-driven form of RCD. Recent studies suggest that therapies which target ferroptosis are promising treatment strategies for CRC. However, a greater understanding of the mechanisms of ferroptosis initiation, propagation, and resistance in CRC is needed. This review provides an overview of recent research in ferroptosis and its potential role as a therapeutic target in CRC. We also propose future research directions that could help to enhance our understanding of ferroptosis in CRC.

© 2023. The Author(s), under exclusive licence to Springer Nature Limited.

Address: Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT, 06510, USA.; Department of Pathology, Yale School of Medicine, New Haven, CT, USA.; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.; Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT, 06510, USA. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.